Key result
The RE-VERSE AD trial is a global phase 3 prospective cohort study designed to investigate idarucizumab in dabigatran-treated patients with severe bleeding or requiring urgent surgery.
Authors
Loading...
Establishes dedicated reversal for dabigatran emergencies; extends targeted antidote options beyond nonspecific agents.
Cohort
Yes
Reilly et al. (2015) conducted a cohort in Dabigatran-treated patients with uncontrollable or life-threatening bleeding, or requiring urgent surgery or intervention. Idarucizumab was evaluated. The RE-VERSE AD trial is a global phase 3 prospective cohort study designed to investigate idarucizumab in dabigatran-treated patients with severe bleeding or requiring urgent surgery.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: